Leadership Shuffle at Biocon, Names Shreehas Tambe as CEO & MD and Kedar Upadhye as CFO

Additionally, Kedar Upadhye has been appointed as the Chief Financial Officer of Biocon Limited.

Biocon Limited has appointed Shreehas Tambe as its Chief Executive Officer and Managing Director, effective April 1, 2026, following approvals from the Nomination and Remuneration Committee and the Board of Directors. 

As the first CEO of the integrated Biocon, Tambe will lead the combined platform that encompasses biosimilars and generics, enhancing the company's ability to operate at scale and compete effectively in global markets. 

Additionally, Kedar Upadhye has been appointed as the Chief Financial Officer of Biocon Limited. 

This leadership transition is part of the complete integration of Biocon Biologics Limited as a wholly owned subsidiary of Biocon Limited, which aims to create a simplified and unified corporate structure.

The strengthened enterprise is well-positioned to lead in diabetes, obesity, oncology, and immunology through a distinct portfolio that includes biosimilars, insulins, complex generics, and peptides, such as GLP-1 therapies.

Kiran Mazumdar-Shaw, Executive Chairperson, Biocon Limited, said, “Biocon has consistently grown by anticipating patient needs and building ahead of the curve. With the integration of our generics and biosimilars businesses, we are creating a uniquely positioned, globally scaled biopharma enterprise. Shreehas has been at the forefront of this transformation, leading several strategic milestones, including the acquisition and integration of the Viatris biosimilars business and the expansion of our global footprint. Under his leadership, Biocon Biologics has emerged as one of the world’s top five biosimilar companies, with a valuation of USD 5.5 billion. As the first CEO to lead the combined business, Shreehas brings deep scientific expertise, strategic rigor, and a steadfast commitment to advancing affordable healthcare. I am confident he will drive disciplined execution and translate our scale into sustained global leadership.”

Speaking on Siddharth Mittal’s contributions, Mazumdar-Shaw added, “I would like to thank Siddharth for his tremendous contributions to Biocon. Since joining in 2013, he has served with distinction as Chief Financial Officer and later as CEO & Managing Director, playing a pivotal role in shaping the company’s growth trajectory. He will now transition to another leadership role within the Biocon Group.”

Shreehas Tambe joined Biocon nearly three decades ago as a management trainee and has since held several leadership roles, playing a crucial part in expanding multiple global businesses. 

During his tenure as the CEO and Managing Director of Biocon Biologics, the company became one of the world’s top five biosimilar companies by revenue, achieving a valuation of USD 5.5 billion in 2025. He successfully led the transformative acquisition of Viatris’ biosimilars business and managed its swift consolidation, establishing a fully integrated, lab-to-patient global biologics enterprise.

Prior to this, Shreehas served as the Chief Operating Officer and later as the Deputy CEO of Biocon Biologics, where he focused on driving enterprise-wide operations and global growth.

Earlier in his career at Biocon, he spearheaded the global expansion of the insulins business, including the establishment of Asia’s largest integrated insulins facility in Malaysia. Shreehas began his career in Research & Development and holds 61 patents, showcasing his dedication to fostering innovation.

As the first CEO & Managing Director of the combined business, he will be responsible for strengthening Biocon’s position as a global biopharma leader that is addressing the world’s most pressing healthcare needs by advancing a differentiated portfolio of biosimilars, insulins, generics and peptides (GLP‑1s).

Shreehas Tambe, CEO & Managing Director, Biocon Limited, said, “It is an honor and privilege to lead Biocon at such a pivotal moment, as we bring together our biologics and generics businesses to build a leading global medicines company. Biocon is among the few organizations that have transformed access to life-saving treatments by effectively leveraging science and technology. Our success has been driven by exceptional talent, united by a strong sense of purpose and an unwavering commitment to serving patient needs. As we expand our portfolio and global presence, my focus will be on strengthening our foundation, consolidating our business, and accelerating sustainable growth. I am deeply grateful to our visionary Chairperson Kiran Mazumdar-Shaw and the Board of Directors for the trust and confidence placed in me and look forward to building on Biocon’s strong legacy to make a meaningful difference for patients worldwide.”

Stay tuned for more such updates on Digital Health News